Obesity Drugs: Pharma giant's leader predicts end of obesity, criticizes Finland's approach

Patrik Jonsson, an executive at pharmaceutical giant Eli Lilly, is strongly advocating for increased public funding for obesity treatments in Finland. He argues that more people should have access to these medications through public healthcare.

Jonsson, who leads Eli Lilly's international business operations, expressed his views forcefully from the company's Swedish office in Solna. He believes Finland's current system, where the vast majority of individuals bear the high cost of obesity drugs out-of-pocket, is inadequate.

Pharmaceutical companies, including Eli Lilly, have been lobbying for years to have these medications included in the national Kela reimbursement system. Jonsson's comments suggest a growing impatience with the slow pace of change in Finland's healthcare policy regarding obesity.

The article highlights that obesity medications are currently very expensive in Finland, and the burden of payment falls primarily on the patients. Jonsson's stance implies that this situation hinders effective obesity management and disproportionately affects those with lower incomes.

“

More people should have access to obesity treatment with public funds.